PP-166 Microtubule Inhibition Therapy by Colchicine in Severe Myocarditis Especially Caused by Epstein-Barr and Cytomegalovirus Co-infection During a Two-Year Period: A Novel Therapeutic Approach




Objective


The form of EBV/CMV co-infection gains rarely multi- pathogenicity and leads to viral myocarditis. Also, it may lead to progressive heart failure or sudden death. The aim of this study is to investigate the impact of low-dose colchicine therapy as adjunt to conventional heart failure therapy in the five patients with EBV/CMV co-infection leads to viral myocarditis.




Methods and Results


We evaluated those patients who stayed in the hospital for the treatment of all myocarditis that fulfilled requirements according to “Expanded Criteria for Diagnosis of Myocarditis” during a two year period. Also, physical, serological and biochemical examinations of the patients suspected from viral myocarditis were analysed. EBV, CMV and other viral antibodies were determined by the ELISA assay. Adjuvant low-dose colchicine therapy (2×0.5 mg twice daily) was prescribed for the conventional heart failure therapy of the five patients were detected EBV/CMV co- infection and the therapy continued for two years. EBV and CMV antibodies of these patients were found positive by ELISA method. In their echocardiographic (ECHO) examinations, the Ejection Fractions (EFs) were 21%, 18%, 25%, 24% and 21% respectively before low-dose colchicine therapy. Also, after two years low-dose adjuvant colchicine therapy EFs were increased to 59%, 42%, 40%, 25% and 41%, respectively. Currently, all patients were clinically stable condition.




Methods and Results


We evaluated those patients who stayed in the hospital for the treatment of all myocarditis that fulfilled requirements according to “Expanded Criteria for Diagnosis of Myocarditis” during a two year period. Also, physical, serological and biochemical examinations of the patients suspected from viral myocarditis were analysed. EBV, CMV and other viral antibodies were determined by the ELISA assay. Adjuvant low-dose colchicine therapy (2×0.5 mg twice daily) was prescribed for the conventional heart failure therapy of the five patients were detected EBV/CMV co- infection and the therapy continued for two years. EBV and CMV antibodies of these patients were found positive by ELISA method. In their echocardiographic (ECHO) examinations, the Ejection Fractions (EFs) were 21%, 18%, 25%, 24% and 21% respectively before low-dose colchicine therapy. Also, after two years low-dose adjuvant colchicine therapy EFs were increased to 59%, 42%, 40%, 25% and 41%, respectively. Currently, all patients were clinically stable condition.

Only gold members can continue reading. Log In or Register to continue

Nov 30, 2016 | Posted by in CARDIOLOGY | Comments Off on PP-166 Microtubule Inhibition Therapy by Colchicine in Severe Myocarditis Especially Caused by Epstein-Barr and Cytomegalovirus Co-infection During a Two-Year Period: A Novel Therapeutic Approach
Premium Wordpress Themes by UFO Themes